Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Exploring Rare Gynecologic Tumors: A Cutting-Edge Perspective on Modern Diagnostic...
share announcement

Exploring Rare Gynecologic Tumors: A Cutting-Edge Perspective on Modern Diagnostic and Therapeutic Strategies

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gynecologic Oncology".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 161

Special Issue Editors

Dr. Brigida Anna Maiorano

E-Mail Website
Guest Editor
Department of Medical Oncology, IRCCS San Raffaele Hospital, 20132 Milan, Italy
Interests: gynecological tumors; genito-urinary tumors; immunotherapy; PARPis; meta-analysis; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Vera Loizzi

E-Mail Website
Guest Editor
Dipartimento interdisciplinare di Medicina (DIM), Università degli studi di Bari Aldo Moro, 70121 Bari, Italy
Interests: cervical cancer; ovarian cancer; endometrial cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The classification of gynecological tumors has changed in recent years, and various rare variants of the disease have been described or re-classified. At the same time, pathological and radiological criteria for their diagnosis, molecular profiling, and subsequent clinical treatment modalities have been widely developed. 

This Special Issue aims to give readers (gynecologists, oncologists, pathologists, radiologists, and radiotherapists) a clear picture of the new landscape of rare gynecological tumors. It will focus on modern techniques for differential diagnoses and the appropriate clinical management of several diseases that, due to their rarity, are almost forgotten about in the medical literature, aiming to increase the body of knowledge on these tumors.

This Special Issue will accept systematic and narrative reviews, original articles, case reports, and all other types of scientific papers.

I look forward to receiving your contributions.

Dr. Brigida Anna Maiorano
Dr. Vera Loizzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vulvar cancer
  • rare gynecological tumor
  • Paget disease
  • uterine sarcoma
  • vaginal cancer
  • ovarian cancer
  • rare gynecological cancer
  • small cell carcinoma genital tract

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2594 KiB  
Article
Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients
by Yiqin Wang, Linlin Bo, Xiaowei Fan, Nan Kang, Xiaobo Zhang, Li Tian, Rong Zhou and Jianliu Wang
Curr. Oncol. 2025, 32(6), 317; https://doi.org/10.3390/curroncol32060317 - 30 May 2025
Abstract
Objectives: The objective of this study was to investigate the significance of molecular classification in guiding treatment decisions for patients with endometrial cancer (EC) or atypical hyperplasia (AH) undergoing fertility-sparing treatment (FST), particularly for those with non-NSMP subtypes. Methods: We conducted a retrospective [...] Read more.
Objectives: The objective of this study was to investigate the significance of molecular classification in guiding treatment decisions for patients with endometrial cancer (EC) or atypical hyperplasia (AH) undergoing fertility-sparing treatment (FST), particularly for those with non-NSMP subtypes. Methods: We conducted a retrospective cohort study involving EC/AH patients undergoing FST and molecular classification using next-generation sequencing at Peking University People’s Hospital between June 2020 and September 2023. Results: A total of 118 EC/AH patients were included, including 92 cases with NSMP, 11 with MMRd, 11 with POLEmut, and 4 with p53abn. (1) Of the 11 patients with MMRd, 6 achieved a complete response (CR) with 1 case receiving progestin, 3 cases showed insensitivity to the initial progestin before transitioning to a combined regimen of progestin and a PD-1 inhibitor, and 2 cases initially received progestin plus a PD-1 inhibitor. There were no significant differences in the cumulative CR rates between the MMRd and NSMP subgroups but a trend of a lower relapse-free-survival (RFS) rate for the MMRd subgroup (p = 0.074). (2) Of the 11 cases with POLEmut, 10 achieved CR but 4 relapsed. There was also a trend for a lower RFS rate in the POLEmut patients (p = 0.069) compared with the NSMP subgroup. (3) Three of the four patients with p53mut achieved CR after treatment with the GnRHa plus LNG-IUS regimen. Conclusion: The selection of appropriate regimens may improve FST outcomes in EC/AH patients with molecular classification of non-NSMP subtypes. Immunotherapy is an effective fertility-preserving approach for patients with MMRd. Full article
(This article belongs to the Special Issue Exploring Rare Gynecologic Tumors: A Cutting-Edge Perspective on Modern Diagnostic and Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop